Company / Free Cash Flow
Rapport Therapeutics, Inc. Free Cash Flow History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$67.2M
FY2024
5-year range
-$67.2M / -$28.8M
FY2023-FY2024
Trend
-133.3%
vs FY2023
Sector context
#85 of 194
Health Care
What the data says
At -$67M, Rapport Therapeutics, Inc.'s free cash flow ranks #85 of 194 in the Health Care sector.
Based on SEC 10-K filings.
-$67M in FY2024.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#85 of 194 in Health CareTop 44% of 194This company -$67.2M Sector average $470.6M
▼
-114.3% below sector average
Key checks
Key Insights
- In FY2024, free cash flow decreased 133.3% year-over-year.
- Ranks #85 out of 194 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 13.36 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$67.2M | -133.3% |
| FY2023 | -$28.8M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026